Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Deciphera Pharmaceuticals, Inc.    DCPH

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 27.61 USD
Weaknesses
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's earnings releases usually do not meet expectations.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
DECIPHERA PHARMACEUTICALS, ..63.08%1 734
-
GILEAD SCIENCES3.77%82 206
VERTEX PHARMACEUTICALS6.35%45 297
REGENERON PHARMACEUTICALS-19.63%32 847
WUXI APPTEC CO., LTD.65.51%20 231
GENMAB32.04%13 665
NEUROCRINE BIOSCIENCES, INC..34.13%8 771
BEIGENE, LTD.-5.69%8 020
HUALAN BIOLOGICAL ENGINEERI..--.--%7 289
SAREPTA THERAPEUTICS, INC.-21.41%6 376
AMARIN CORPORATION PLC18.52%5 762
REATA PHARMACEUTICALS, INC.229.61%5 567
TONGHUA DONGBAO PHARMACEUTI..24.82%4 983
EXELIXIS, INC.-16.52%4 974
BLUEBIRD BIO, INC.-9.75%4 948
ASCENDIS PHARMA A/S57.85%4 702
More Results
Financials (USD)
Sales 2019 25,6 M
EBIT 2019 -174 M
Net income 2019 -169 M
Finance 2019 361 M
Yield 2019 -
P/E ratio 2019 -8,34x
P/E ratio 2020 -7,32x
EV / Sales2019 53,7x
EV / Sales2020 129x
Capitalization 1 734 M
Upcoming event on DECIPHERA PHARMACEUTICALS,
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes